• Executive Chair

    Jan Ohrstrom

    Board Chair

    Jan Ohrstrom is Chair of the Board and Non-Executive Director of ONWARD since 2016. He has over 30 years of experience in the medical technology and pharmaceutical industries, and has a proven track record driving successful product approvals, private financings, and IPOs. Jan has held senior management roles at NovoNordisk, ProFibrix BV and ZymoGenetics, among others. He is currently CEO of VarmX BV, a company specializing in blood clotting agents, and is chairman of Blaze Bioscience Inc. Jan holds an MD from the University of Copenhagen.
  • John de Koning LSP

    John de Koning

    Non-Executive Director

    John de Koning is a Non-Executive Director of ONWARD since 2016. He is a General Partner at LSP, one of the largest European investment firms providing financing for life sciences and health care companies. Since joining the LSP in 2006, John has led some of its most successful investments and served on the board of several companies, including argenx, Merus, and Prosensa. John holds an MS in Molecular Biology from the University of Utrecht and a PhD in Oncology from the Erasmus University Rotterdam.
  • Patrick Van Beneden

    Patrick Van Beneden

    Non-Executive Director

    Patrick Van Beneden is a Non-Executive Director of ONWARD since 2016. He is an Associate Partner at Gimv NV, a leading European private equity firm. As Partner of GIMV for 35 years, Patrick has established a stellar track record in early and late-stage investments in the life sciences, including Devgen, CropDesign, Plexxikon, and Endosense. He is a board member of FIRE1, Biotalys, and JenaValve Technology. Patrick holds a Master’s degree in Financial Sciences from VLEKHO Business School in Brussels.
  • Regina Hodits

    Regina Hodits

    Non-Executive Director

    Regina Hodits is a Non-Executive Director of ONWARD since 2019. She has over 20 years of experience in venture capital and is a managing partner at Wellington Partners Life Science Venture Capital Consulting GmbH, focusing on early-stage and growth investments. Before joining Wellington, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was a founding investor in Bicycle Therapeutics, F-star and JenaValve, and currently serves on the boards of Ayoxyya, Carisma, Sidekick, SNIPR Biome, and Stipe. Regina holds PhD in Biochemistry from the Technical University of Vienna.
  • Roel Bulthuis

    Roel Bulthuis

    Non-Executive Director

    Roel Bulthuis is a Non-Executive Director of ONWARD since 2016. He combines almost 20 years of experience across venture capital, pharma business development, and investment banking at M-Ventures, Merck Serono and Fortis Bank. Roel is currently Managing Partner at INKEF capital and the head of its healthcare investment team. A graduate of the prestigious Kauffman Fellows program, he serves as a director of ten companies. Roel holds an MS in Biopharmaceutical Sciences from Leiden University and an MBA in Finance from the Helsinki School of Economics.
  • Ian Curtis

    Ian Curtis

    Non-Executive Director

    Ian Curtis is a Non-Executive Director of ONWARD since 2019. As the father of a young woman living with SCI, Ian is passionate about advancing research and treatment for SCI. He is a member of the board of the Christopher and Dana Reeve Foundation, the International Spinal Research Trust, and the Neurokinex Charitable Trust, which operates activity-based rehabilitation clinics in the UK. Ian holds a BA in History from Durham University and is a member of the Institute of Chartered Accountants in England and Wales.
  • Fred Colen

    Fred Colen

    Non-Executive Director

    Fred Colen is a Non-Executive Director of ONWARD since 2017. With over 40 years of experience in the medical device industry, Fred has a track record in building strong organizations to bring new technology to market. Fred is President and CEO of Neovasc Inc., a Canadian publicly traded company developing products for the cardiovascular marketplace. Previously, he held senior executive roles at Boston Scientific and St Jude Medical. He holds Master’s degrees in Electrical Engineering and Medical Technology from RWTH Aachen University, Germany.
    Independent Director
  • Dave Marver, CEO

    Dave Marver

    Chief Executive Officer

    Dave Marver joined ONWARD in July 2020. An accomplished chief executive and director with more than 25 years of international experience in public, private, and emerging companies, he combines expertise in medical and consumer technology, wearables, and health monitoring. Previously, Dave spent almost 15 years with Medtronic in a variety of leadership positions in the US and Europe, including Vice President roles in Sales, Marketing, Strategy, and Business Development. He then joined NASDAQ-listed Cardiac Science Corporation as CEO, before co-founding two start-ups. He holds a BA in Psychology from Duke University and an MBA from University of California Los Angeles.
  • Grégoire Courtine, PhD, CSO

    Grégoire Courtine, PhD

    Chief Scientific Officer

    Prof. Grégoire Courtine is the co-founder of ONWARD and its Chief Scientific Officer as well as a Non-Executive Director. His ground-breaking research in neuroscience has been recognized by several prestigious prizes, including the Rolex Award, the Schellenberg Research Prize and the Chancellor’s Award of the University of California. Grégoire is a full professor of neuroscience and neurotechnology at the Swiss Federal Institute of Technology (EPFL) and Director of NeuroRestore, a research center at EPFL and the University Hospital of Lausanne that develops innovative therapies using neurostimulation and other approaches. He holds a PhD in Neurosciences from INSERM, Paris, and a PhD in Medicine from the University of Pavia, Italy.